Article Text
Abstract
The use of placebo as a control condition in clinical trials of major depressive disorder and anxiety disorders continues to be an area of ethical concern. Typically, opponents of placebo controls argue that they violate the beneficent-based, “best proven diagnostic and therapeutic method” that the original Helsinki Declaration of 1964 famously asserted participants are owed. A more consequentialist, oppositional argument is that participants receiving placebo might suffer enormously by being deprived of their usual medication(s). Nevertheless, recent findings of potential for suicidality in young people treated with antidepressants, along with meta-analyses suggesting that antidepressants add no significant clinical benefit over placebos, warrant a re-evaluation of the arguments against placebo. Furthermore, the nature of placebo treatment in short-term clinical trials is often not well understood, and lack of understanding can foster opposition to it. This paper will show how scientific justifications for placebo use are morally relevant. The fundamental ethical importance of placebo controls is discussed in relation to several aspects of clinical trials, including detection of adverse events, accurate assessment of clinical benefit, advancing understanding of the heterogeneity of depression and anxiety disorders and respecting informed consent requirements. Prohibiting the use of placebo controls is morally concerning in that such prohibitions allow for the possibility of serious adverse public health consequences. Moral worries that research participants receiving placebo are being unduly jeopardised will be shown to be exaggerated, especially in relation to the net benefits for end-users to be gained from the quality of data resulting from using placebo controls.
Statistics from Altmetric.com
Linked Articles
- The concise argument
Read the full text or download the PDF:
Other content recommended for you
- Ketamine for treatment-resistant depression: recent developments and clinical applications
- Empirical evidence against placebo controls
- Efficacy of repeated intravenous esketamine in adolescents with anxious versus non-anxious depression
- Stepped care for depression and anxiety in visually impaired older adults: multicentre randomised controlled trial
- Treatment of anxiety and depressive disorders in patients with cardiovascular disease
- Anxiety and depressive disorders are associated with delusional-like experiences: a replication study based on a National Survey of Mental Health and Wellbeing
- Migraine and its psychiatric comorbidities
- What proportion of initially prescribed antidepressants is still being prescribed chronically after 5 years in general practice? A longitudinal cohort analysis
- Randomised placebo-controlled trials of surgery: ethical analysis and guidelines
- Medicalising unhappiness: new classification of depression risks more patients being put on drug treatment from which they will not benefit